By combining predictive modeling with cheminformatics and in silico screening, we are systemically advancing CDK inhibitors – like CDK9 – for hard-to-treat cancers.
Fighting cancer requires a powerful arsenal of targeted therapies. That’s why we’re building a pipeline of small molecules that inhibit cyclin-dependent kinases (CDKs) to disrupt cancer cell growth at its core.
